Analyst Research Report Snapshot

Title:

Regulus Therapeutics Inc. (RGLS) - Financial Analysis Review

Price:

$125.00

Provider:

GlobalData

Date:

19 Mar 2014

Pages:

33

Type:

AcrobatPDF

Companies referenced:

RGLS.OQ

Available for Immediate Download
Summary:

Regulus Therapeutics Inc. (RGLS) - Financial Analysis Review Summary Regulus Therapeutics Inc. (Regulus Therapeutics) is a biopharmaceutical company. The company discovers, develops and commercializes microRNA therapeutics. Its products are used for the therapeutic conditions of hepatitis C infection, cardiovascular disease, cancer, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. The company’s research and development activities are focused on the development of RNA-based therapeutics targeting micro RNA. GlobalData's Regulus Therapeutics Inc. (RGLS) - Financial Analysis Review provides a comprehensive insight into the company's history, business structure and operations. The report contains information on the company's key employees, key competitors and major products and services, as well as detailed financial ratios for the last 5 years. Regulus Therapeutics Inc. Key Recent Developments: Feb 27, 2014: Regulus Provides Strategic Update and Reports Fourth Quarter and Year-End 2013 Financial Results and Recent Highlights Feb 13, 2014: Regulus Appoints Head of Regulus microMarkers R&D Division Feb 04, 2014: Regulus Strengthens Executive Management Team with Addition of David Szekeres as Chief Business Officer and General Counsel Feb 04, 2014: Regulus Therapeutics, Inc. Strengthens Executive Management Team With Addition Of David Szekeres As Chief Business Officer And General Counsel Jan 13, 2014: Regulus Expands its Biomarkers Platform and Establishes Regulus microMarkers, a New R&D Division Focused on Identifying microRNAs as Biomarkers of Disease This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better. Scope - Business description - A detailed description of the company's operations and business divisions. - Company history - Progression of key events associated with the company. - Major products and services - A list of major products, services and brands of the company. - Key competitors - A list of key competitors to the company. - Key employees - A list of the key executives of the company. - Executive biographies - A brief summary of the executives' employment history. - Key operational heads - A list of personnel heading key departments/functions. - Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details. - Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. Note: Some sections may be missing if data is unavailable for the company. Reasons to Buy - Gain key insights into the company for academic or business research purposes. Key elements such as detailed business description and financial ratios and charts are incorporated in the profile to assist your academic or business research needs. - Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services. - Examine potential investment and acquisition targets with this report's detailed insight into the company's business, financial and operational performance. Financial r...

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.